Impact of crisaborole & tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children with atopic dermatitis

Poor quality of life (QoL) is common in children with atopic dermatitis (AD) and their caregivers. This study used patient-reported outcomes (PROs) to monitor the impact of crisaborole (CRIS) and tacrolimus 0.03% (TAC) on children (2-15 years) with mild/moderate AD and on caregiver burden. This open-label study randomized 47 child-caregiver dyads to CRIS or TAC for 12 weeks. Disease severity (Eczema Area & Severity Index [EASI], % body surface area, Investigator Global Assessment [IGA]), QoL (Children’s Dermatology Life Quality Index, Family Dermatology Life Quality Index), itch (PROMIS Peds Itch-Short Form), anxiety (PROMIS Anxiety-Peds), pain interference (PROMIS Pain Interference-Peds), depression (PROMIS Depression-Peds), sleep (Children’s Sleep Habits Questionnaire), and caregiver burden (Caregiver Burden Inventory) were assessed at baseline, 6 and 12 weeks.